Tighe Reardon, Acting Chief Financial Officer at Janux Therapeutics, Inc. (JANX), sold 1,514,246 shares at $54.75 ($82.9M) on 2024-06-03, disclosed to the SEC on 2024-06-05.
Open-market sale of $82.9M JANX by Acting Chief Financial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $54.75 | 131,196 | $7.2M | 8.7% |
| 2 | $54.75 | 691,525 | $37.9M | 45.7% |
| 3 | $54.75 | 691,525 | $37.9M | 45.7% |
| Total | $54.75 avg | 1,514,246 | $82.9M | 100% |
| Filing → |
| THOR | BUY | 2018-12-13 | $6.0M | — | Filing → |